Nanomix Corporation Announces Securities Purchase Agreement With GHS Investments for up to $3.0 Million

Rhea-AI Summary

Nanomix Corporation (OTC-PINK: NNMXD) has entered a $3 million securities purchase agreement with GHS Investments, LLC. This marks a significant transition for Nanomix from development to commercial operations. GHS, known for investing in promising small-cap companies, is expected to be a valuable partner. The agreement allows Nanomix to sell up to $3 million of common stock to GHS over several months. Nanomix specializes in mobile, point-of-care diagnostics, aiming to enhance healthcare delivery with rapid diagnostic solutions.

Positive

• Entered into a $3 million securities purchase agreement with GHS Investments.
• Partnership with GHS expected to aid transition to commercial operations.
• Focus on mobile, point-of-care diagnostics aligns with critical healthcare needs.

Negative

• None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, announces it has entered into a $3.0 million securities purchase agreement with GHS Investments, LLC (GHS), a leading private investment and management group.

“This agreement is an important step in the transition of our business from development stage to commercial operations. GHS has an impressive track record of investing in small-cap companies with a promising outlook, and we believe they will be a valuable partner to Nanomix,” stated David Ludvigson, President and Chief Executive Officer of Nanomix.

Under the terms of the securities purchase agreement, Nanomix will have the right to sell up to $3.0 million of common stock to GHS across multiple tranches over the next several months. For more information on the agreement, please refer to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange and available at www.sec.gov.

About Nanomix Corporation

Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit www.nano.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005085/en/

LHA Investor Relations

Tirth Patel

212-201-6614

tpatel@lhai.com

Source: Nanomix Corporation

FAQ

What is the significance of the $3 million agreement for Nanomix (NNMXD)?

The $3 million securities purchase agreement signifies Nanomix's transition from development to commercial operations, providing necessary capital.

Who is GHS Investments in relation to Nanomix (NNMXD)?

GHS Investments, LLC is a private investment group that has partnered with Nanomix to support its growth and commercial strategies.

How will the $3 million related to Nanomix (NNMXD) be utilized?

Nanomix plans to use the funds from the agreement across multiple tranches to support its transition and operational needs.

What is Nanomix Corporation (NNMXD) focused on?

Nanomix Corporation focuses on developing mobile point-of-care diagnostics to improve healthcare delivery and patient outcomes.

What types of products is Nanomix (NNMXD) developing?

Nanomix is developing rapid diagnostic assays aimed at critical infections and other health conditions to enable quicker clinical decisions.